D H Gonzales

Summary

Affiliation: Oregon Health and Science University
Country: USA

Publications

  1. ncbi request reprint Effects of gender on relapse prevention in smokers treated with bupropion SR
    David Gonzales
    Department of Medicine, Oregon Health and Science University, Portland 97201, USA
    Am J Prev Med 22:234-9. 2002
  2. ncbi request reprint Support for spirituality in smoking cessation: results of pilot survey
    David Gonzales
    OHSU Smoking Cessation Center, Division of Pulmonary and Critical Medicine, Department of Medicine, Oregon Health and Science University, Portland, OR 97239 3098, USA
    Nicotine Tob Res 9:299-303. 2007
  3. ncbi request reprint Bupropion SR as an aid to smoking cessation in smokers treated previously with bupropion: a randomized placebo-controlled study
    D H Gonzales
    Oregon Health Sciences University, Portland, 97201, USA
    Clin Pharmacol Ther 69:438-44. 2001
  4. pmc Immediate versus delayed quitting and rates of relapse among smokers treated successfully with varenicline, bupropion SR or placebo
    David Gonzales
    OHSU Smoking Cessation Center, Department of Medicine, Oregon Health and Science University, 3181 SW Sam Jackson Park Road, Portland, OR 97239 3098, USA
    Addiction 105:2002-13. 2010
  5. ncbi request reprint Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial
    David Gonzales
    Smoking Cessation Center, Department of Medicine, Oregon Health and Science University, Portland, OR 97239, USA
    JAMA 296:47-55. 2006
  6. ncbi request reprint Bupropion for pharmacologic relapse prevention to smoking: predictors of outcome
    Richard D Hurt
    Nicotine Research Center, Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA
    Addict Behav 27:493-507. 2002
  7. ncbi request reprint Bupropion SR for relapse prevention: a "slips-allowed" analysis
    Michael J Durcan
    Smoking Control, GlaxoSmithKline, 1500 Littleton Road, Parsippany, NJ 07054, USA
    Am J Health Behav 28:456-63. 2004
  8. ncbi request reprint The effect of bupropion sustained-release on cigarette craving after smoking cessation
    Michael J Durcan
    GlaxoSmithKline, Research Triangle Park, North Carolina 27709, USA
    Clin Ther 24:540-51. 2002
  9. ncbi request reprint Smoking cessation with varenicline, a selective alpha4beta2 nicotinic receptor partial agonist: results from a 7-week, randomized, placebo- and bupropion-controlled trial with 1-year follow-up
    Mitchell Nides
    Los Angeles Clinical Trials, 2990 S Sepulveda Boulevard, Los Angeles, CA 90064, USA
    Arch Intern Med 166:1561-8. 2006
  10. ncbi request reprint Efficacy and safety of the novel selective nicotinic acetylcholine receptor partial agonist, varenicline, for smoking cessation
    Cheryl Oncken
    University of Connecticut Health Center, 263 Farmington Avenue, Farmington, CT 06030, USA
    Arch Intern Med 166:1571-7. 2006

Detail Information

Publications11

  1. ncbi request reprint Effects of gender on relapse prevention in smokers treated with bupropion SR
    David Gonzales
    Department of Medicine, Oregon Health and Science University, Portland 97201, USA
    Am J Prev Med 22:234-9. 2002
    ..Lower abstinence and higher relapse rates are often reported for women treated with NRT. Gender effects for those treated with non-nicotinic, bupropion-hydrochloride sustained release for relapse prevention have not been studied...
  2. ncbi request reprint Support for spirituality in smoking cessation: results of pilot survey
    David Gonzales
    OHSU Smoking Cessation Center, Division of Pulmonary and Critical Medicine, Department of Medicine, Oregon Health and Science University, Portland, OR 97239 3098, USA
    Nicotine Tob Res 9:299-303. 2007
    ..We conclude that smokers, especially heavier smokers, may be receptive to using spiritual resources in a quit attempt and that spirituality in tobacco dependence treatment warrants additional investigation and program development...
  3. ncbi request reprint Bupropion SR as an aid to smoking cessation in smokers treated previously with bupropion: a randomized placebo-controlled study
    D H Gonzales
    Oregon Health Sciences University, Portland, 97201, USA
    Clin Pharmacol Ther 69:438-44. 2001
    ..In particular, the effect of repeated use of bupropion SR (Zyban; INN, amfebutamone) on abstinence rates has not been studied previously...
  4. pmc Immediate versus delayed quitting and rates of relapse among smokers treated successfully with varenicline, bupropion SR or placebo
    David Gonzales
    OHSU Smoking Cessation Center, Department of Medicine, Oregon Health and Science University, 3181 SW Sam Jackson Park Road, Portland, OR 97239 3098, USA
    Addiction 105:2002-13. 2010
    ..We assessed to what degree smokers who fail to quit on the target quit date (TQD) or lapse following TQD eventually achieve success with continued treatment...
  5. ncbi request reprint Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial
    David Gonzales
    Smoking Cessation Center, Department of Medicine, Oregon Health and Science University, Portland, OR 97239, USA
    JAMA 296:47-55. 2006
    ..The alpha4beta2 nicotinic acetylcholine receptors (nAChRs) are linked to the reinforcing effects of nicotine and maintaining smoking behavior. Varenicline, a novel alpha4beta2 nAChR partial agonist, may be beneficial for smoking cessation...
  6. ncbi request reprint Bupropion for pharmacologic relapse prevention to smoking: predictors of outcome
    Richard D Hurt
    Nicotine Research Center, Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA
    Addict Behav 27:493-507. 2002
    ..These data should encourage others to perform similar pharmacologic relapse prevention studies with this or other pharmacotherapies...
  7. ncbi request reprint Bupropion SR for relapse prevention: a "slips-allowed" analysis
    Michael J Durcan
    Smoking Control, GlaxoSmithKline, 1500 Littleton Road, Parsippany, NJ 07054, USA
    Am J Health Behav 28:456-63. 2004
    ..To assess the efficacy of bupropion SR on smoking abstinence using a "slips allowed" analysis...
  8. ncbi request reprint The effect of bupropion sustained-release on cigarette craving after smoking cessation
    Michael J Durcan
    GlaxoSmithKline, Research Triangle Park, North Carolina 27709, USA
    Clin Ther 24:540-51. 2002
    ..The effect of continued use of pharmacotherapy for smoking cessation on relapse rates is unknown. Bupropion sustained-release (SR) is the first non-nicotine-based therapy that is effective for achieving abstinence from smoking...
  9. ncbi request reprint Smoking cessation with varenicline, a selective alpha4beta2 nicotinic receptor partial agonist: results from a 7-week, randomized, placebo- and bupropion-controlled trial with 1-year follow-up
    Mitchell Nides
    Los Angeles Clinical Trials, 2990 S Sepulveda Boulevard, Los Angeles, CA 90064, USA
    Arch Intern Med 166:1561-8. 2006
    ..This study evaluated the efficacy, tolerability, and safety of 3 varenicline doses for smoking cessation. Bupropion hydrochloride was included as an active control...
  10. ncbi request reprint Efficacy and safety of the novel selective nicotinic acetylcholine receptor partial agonist, varenicline, for smoking cessation
    Cheryl Oncken
    University of Connecticut Health Center, 263 Farmington Avenue, Farmington, CT 06030, USA
    Arch Intern Med 166:1571-7. 2006
    ....
  11. ncbi request reprint Comment: Oral varenicline for smoking cessation
    David Gonzales
    Ann Pharmacother 41:720-1. 2007